...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI EAACI Taskforce on Immunopharmacology position paper
【24h】

Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI EAACI Taskforce on Immunopharmacology position paper

机译：比较生物学和小分子药物治疗慢性呼吸系统疾病：免疫医药地位纸的EAACI EAACI任务性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Chronic airway diseases such as asthma and chronic obstructive pulmonary disease ( COPD ), together with their comorbidities, bear a significant burden on public health. Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens. On the other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process. Antibody‐based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD , biologicals are having a more limited impact. Small molecule drug ( SMD )‐based therapies represent an active field in pharmaceutical research and development. SMD s expand biologicals’ therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically based formulation, offering both convenience and lower costs. Aim of this review was to compare and contrast the distinct pharmacological properties and clinical applications of SMD s‐ and antibody‐based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for these chronic inflammatory respiratory diseases.
机译：摘要慢性气道等哮喘和慢性阻塞性肺病（COPD）以及他们的合并症，对公共卫生承担重大负担。增加炎症气道疾病潜在的分子网络的升值需要转化为New疗法，以进行目前治疗方案未控制的明显表型。另一方面，为这种呼吸系统疾病的新安全和有效疗法的开发是一种艰巨而昂贵的过程。基于抗体（生物）疗法成功治疗不受标准疗法控制的某些呼吸状况，例如严重的过敏性和难治性嗜酸性嗜酸性嗜酸性严重哮喘，而在其他炎症性呼吸系统疾病（例如COPD）中，生物学的影响更有限。基于药物研究和开发的小分子药物（SMD）代表了一种活性领域。 SMD S通过作为口腔或局部的制剂通过递送到达细胞内隔室来扩大生物学的治疗靶，提供便利性和降低成本。本综述的目的是比较和对比基于SMD S和抗体的治疗策略，其局限性和挑战的不同药理性质和临床应用，以突出他们应该如何融入它们的最佳利用并填补批评目前对这些慢性炎症性呼吸疾病治疗的差距。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号